CAS9 fusion proteins and related methods
Inventors
Standage-Beier, Kylie • Balachandran, Parithi • Brookhouser, Nicholas • Brafman, David • Wang, Xiao
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Assignees
Arizona State University Downtown Phoenix campus
SteriTools, LLCSteriTools is developing a De Novo intraoperative device meant to kill bacteria at point of use as part of the normal operating room workflow. Preliminary GLP tests yield a 7-8 log reduction of eight of the major SSI producing microbes in just 15 seconds.
SteriTools is developing a De Novo intraoperative device meant to kill bacteria at point of use as part of the normal operating room workflow. Preliminary GLP tests yield a 7-8 log reduction of eight of the major SSI producing microbes in just 15 seconds.
Abstract
Disclosed are recombinant Cas9 proteins, methods of production, and methods of use for targeted DNA deletions, DNA insertions, or both in a eukaryotic genome. An assay system for evaluating the ability of the recombinant Cas9 proteins for targeted DNA deletions, DNA insertions, or both in a eukaryotic genome is also disclosed.
Core Innovation
The disclosed invention is iCas9, a fusion of catalytically inactive Cas9 and a catalytic domain of a hyperactive Tn3 transposon resolvase, together with guide RNAs that target DNA around a Tn3 core recognition sequence and an accessory sequence. The fusion directs recombination at the core recognition sequence without relying on endogenous DNA repair. The claim specifies the strand and positional relationships of the guide RNAs, while drawings illustrate the system and related guide arrangements.
The disclosure describes a kit containing the fusion protein and guide RNAs, reporting that recombination products match expected junctions without indels compared to wild-type Cas9 integration. Experiments describe donor integration and target deletion, showing an increase in GFP-positive cells when an accessory sgRNA is included. Content also illustrates linker variants associated with differing deletion levels and plasmid maps for the fusion-protein and sgRNA constructs.
Claims Coverage
The claims identify two independent claims covering the fusion protein and a kit comprising the fusion protein and guide RNAs. Two inventive features are identified.
Fusion protein
An independent claim covers a fusion protein consisting of a specified amino acid sequence comprising catalytically inactive Cas9 fused to a catalytic domain of a hyperactive Tn3 transposon resolvase.
Kit for targeted recombination
An independent claim covers a kit comprising the fusion protein, containing linkers and a nuclear localization signal, and three guide RNAs, wherein two guide RNAs target opposite DNA strands flanking a Tn3 core recognition sequence and a third guide RNA targets an adjacent accessory sequence with specified positional relationships.
The independent claims cover the specified Cas9–Tn3 resolvase fusion protein and a kit combining the fusion protein with guide RNAs directed to DNA around a Tn3 core recognition sequence and an adjacent accessory sequence.
Stated Advantages
The described experiments report that including an accessory sgRNA markedly increases GFP-positive cells.
Documented Applications
Use of the kit in a eukaryotic cell to delete a target sequence from its genome.
Use of the kit in a eukaryotic cell to insert an extraneous sequence into a target genomic region.
Experiments involving GFP donor integration and target deletion.
Interested in licensing this patent?
